ANEB Anebulo Pharmaceuticals, Inc.: institutional ownership and insider trading
1 funds reported holding $440K of Anebulo Pharmaceuticals, Inc. in their latest 13F filings; in Q1 2026 funds net bought $0, with 0 new positions and 18 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
ANEB revenue and earnings
- Quarter ended Dec 31, 2025: revenue n/a, net income −$2.00M, EPS -0.05
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.16M, EPS -0.05
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.14M, EPS -0.04
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.68M, EPS -0.04
Largest institutional holders of ANEB
- VANGUARD GROUP INC — $440K
Recent ANEB insider trades
- Dec 23, 2024: English Aron R. bought 10,101,010 shares ($10.0M)
5%+ owners
- Aron R. English: 51.1% (Schedule 13D/A, filed Feb 27, 2025)
- Nantahala Capital Management, LLC: 8.5% (Schedule 13G/A, filed Feb 13, 2026)
- Mangrove Partners IM, LLC: 6.2% (Schedule 13G, filed Mar 17, 2025)
Who owns the most ANEB stock?
The largest institutional holders of Anebulo Pharmaceuticals, Inc. in the latest 13F filings are VANGUARD GROUP INC ($440K).
Are insiders buying or selling ANEB?
No open-market insider buys or sells of Anebulo Pharmaceuticals, Inc. were reported in the last 12 months.